Compare
Solventum Corp vs Baxter International Inc vs ResMed Inc vs West Pharmaceutical Services Inc
| Latest fiscal year | Solventum Corp SOLV | Baxter International Inc BAX | ResMed Inc RMD | West Pharmaceutical Services Inc WST |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $8.32B | $11.24B | $5.65B | $3.07B |
| Revenue growth (YoY) | +0.9% | +5.7% | +9.9% | +6.3% |
| Gross margin | 53.5% | 30.1% | 61.1% | 35.9% |
| Operating margin | 26.2% | -2.7% | 33.4% | 19.0% |
| Net margin | 18.7% | -8.5% | 26.9% | 16.1% |
| Net income | $1.56B | -$957.00M | $1.52B | $493.70M |
| EPS (Diluted) | $8.88 | -$1.87 | $10.43 | $6.79 |
| Operating cash flow | $369.00M | $845.00M | $1.81B | $754.80M |
| Free cash flow | -$10.00M | $332.00M | $1.65B | $468.90M |
| Cash & equivalents | $878.00M | $1.97B | $1.47B | $791.30M |
| Total assets | $14.29B | $20.05B | $8.97B | $4.27B |
| Total liabilities | $9.24B | $13.95B | $2.38B | $1.09B |
| Shareholders' equity | $5.05B | $6.10B | $6.59B | $3.18B |
| Return on year-end equity | 30.8% | -15.7% | 23.1% | 15.5% |
| Shares outstanding | 173.49M | n/a | 144.24M | 72.00M |
Revenue, most recent five fiscal years
| Fiscal year | Solventum Corp | Baxter International Inc | ResMed Inc | West Pharmaceutical Services Inc |
|---|---|---|---|---|
| Latest | $8.32B Ended 2025-12-31 | $11.24B Ended 2025-12-31 | $5.65B Ended 2026-06-30 | $3.07B Ended 2025-12-31 |
| 1 year earlier | $8.25B Ended 2024-12-31 | $10.64B Ended 2024-12-31 | $5.15B Ended 2025-06-30 | $2.89B Ended 2024-12-31 |
| 2 years earlier | $8.20B Ended 2023-12-31 | $10.36B Ended 2023-12-31 | $4.69B Ended 2024-06-30 | $2.95B Ended 2023-12-31 |
| 3 years earlier | $8.13B Ended 2022-12-31 | $10.06B Ended 2022-12-31 | $4.22B Ended 2023-06-30 | $2.89B Ended 2022-12-31 |
| 4 years earlier | n/a | $12.15B Ended 2021-12-31 | $3.58B Ended 2022-06-30 | $2.83B Ended 2021-12-31 |